（文獻(xiàn)來(lái)啦）艾美捷間充質(zhì)干細(xì)胞標(biāo)志物解決方案
間充質(zhì)干細(xì)胞（mesenchymal stem cells，MSCs）是一類(lèi)來(lái)源于中胚層的成體干細(xì)胞，具有自我更新和多向分化的能力。zui常見(jiàn)的MSCs有：骨髓間充質(zhì)干細(xì)胞、脂肪間充質(zhì)干細(xì)胞、胎盤(pán)間充質(zhì)干細(xì)胞、羊膜間充質(zhì)干細(xì)胞、臍帶間充質(zhì)干細(xì)胞等。1995年，由惡性血液病患者的骨髓中獲得并經(jīng)體外培養(yǎng)得到的MSCs被移植回患者體內(nèi)，經(jīng)過(guò)臨床研究顯示這些干細(xì)胞的具有治療潛力，從此，對(duì)MSCs的研究由實(shí)驗(yàn)室進(jìn)入了臨床應(yīng)用。
?
?
目前，市面上MSCs細(xì)胞表面標(biāo)志物特性為：CD105、CD73、CD90等表面標(biāo)志物陽(yáng)性表達(dá)，CD34、CD45等造血系細(xì)胞表面標(biāo)志物或人白細(xì)胞抗原HLA-DR、HLA-DP、HLA-DQ等則基本不表達(dá)。
?
除了上面提到的標(biāo)志物之外，還有沒(méi)有更多相關(guān)抗體呢？
?
艾美捷?Atlas Antibodies?間充質(zhì)干細(xì)胞標(biāo)志物抗體。
蛋白指標(biāo)???????????????貨號(hào)???????????????應(yīng)用類(lèi)型
CD29/ITGB1?HPA059297?IHC, WB
CD105/ENG?HPA011862?IHC, WB
CD73/NT5E?HPA017357?IHC,WB,ICC-IF
CD90/Thy-1?HPA003733?IHC,ICC-IF
CD106/VCAM1?HPA069867?WB, ICC-IF
CD117/KIT?AMAb90901?IHC, WB
CD146/MCAM?HPA008848?IHC, WB
CD166/ALCAM?HPA010926?IHC
CD44/PGP1?HPA005785?IHC,WB,ICC-IF
CD54/ICAM1?HPA002126?IHC, WB
CD56/NCAM1?HPA039835?IHC,WB,ICC-IF
CSPG4/NG2?HPA002951?IHC, WB
GDF-5/BMP14?HPA015648?IHC, WB
ITGA2B/CD41?HPA031170?IHC, WB
MYOG/MYF4?HPA028336?ICC-IF
OSX/SP7?HPA063202?IHC
RUNX2/AML3?HPA022040?IHC,WB,ICC-IF
RUNX3/AML2?HPA059006?IHC, WB
SOX11/SRY (sex determining region Y)-box 11?AMAb90501?IHC,WB,ICC-IF
SOX6/SRY-Box Transcription Factor 6?HPA001923?IHC,ICC-IF
SOX9/CMD1?HPA001758?IHC,WB,ICC-IF
*?僅適用于科研用途.
?
發(fā)表文章（摘取部分）：
1、Alcedo, Karel P., et al. "Tumor‐Selective Altered Glycosylation and Functional Attenuation of CD73 in Human Hepatocellular Carcinoma."Hepatology communications10 (2019): 1400-1414.
2、Haun, Randy S., et al. "Bioorthogonal labeling cell-surface proteins expressed in pancreatic cancer cells to identify potential diagnostic/therapeutic biomarkers."Cancer biology & therapy10 (2015): 1557-1565.
3、Serra, Sara, et al. "CD73-generated extracellular adenosine in chronic lymphocytic leukemia creates local conditions counteracting drug-induced cell death."Blood, The Journal of the American Society of Hematology23 (2011): 6141-6152.
4、Ziebarth, Angela J., et al. "Endoglin (CD105) contributes to platinum resistance and is a target for tumor-specific therapy in epithelial ovarian cancer."Clinical Cancer Research1 (2013): 170-182.
